Thigpen J T, Ehrlich C E, Creasman W T, Curry S, Blessing J A
Am J Clin Oncol. 1983 Jun;6(3):273-5. doi: 10.1097/00000421-198306000-00003.
Twenty-nine patients with advanced or recurrent adenocarcinoma of the ovary no longer responsive to standard treatment measures were given maytansine 1.2 mg/m2 I.V. every 3 weeks. None of the 29 patients demonstrated an objective regression of disease. Eighteen (62%) demonstrated stable disease for 1 or more months, while 11 (38%) developed rapid progression of disease. Adverse effects consisted primarily of leukopenia (7/29), thrombocytopenia (9/29), and nausea and vomiting (14/29). Only one patient developed life-threatening toxicity (platelets less than 25,000 microliters), and no drug-related deaths were observed. Maytansine thus appears inactive in the treatment of adenocarcinoma of the ovary at the dose and schedule tested.
29例对标准治疗措施不再有反应的晚期或复发性卵巢腺癌患者，每3周静脉注射1.2mg/m²美登素。29例患者中无一例显示疾病客观缓解。18例（62%）疾病稳定1个月或更长时间，而11例（38%）疾病迅速进展。不良反应主要包括白细胞减少（7/29）、血小板减少（9/29）以及恶心和呕吐（14/29）。只有1例患者出现危及生命的毒性反应（血小板低于25,000/微升），未观察到与药物相关的死亡。因此，在所测试的剂量和给药方案下，美登素在卵巢腺癌治疗中似乎无活性。
